Form 4: Sarepta Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Michael Severino, Chief Executive Officer and a Director of Sarepta Therapeutics, Inc., reported multiple transactions in common stock on July 28, 2026.
Summary
- Grant/award: acquired 756,104 Common Stock on July 28, 2026; holds 756,104 after (Direct).
- Grant/award: acquired 2,224,342 Stock Options (right to buy) on July 28, 2026; holds 2,224,342 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Michael Severino — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Grant/award | Common Stock | 756,104 | — | — | 756,104 |
| 2026-07-28 | Grant/award | Stock Options (right to buy) | 2,224,342 | — | — | 2,224,342 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Grant/award (756,104 shares) |
| 2026-07-28 | Grant/award (2,224,342 shares) |
Keywords
insider transaction, Form 4, SRPT, Sarepta Therapeutics, Inc., neutral, Michael Severino
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.